Core Insights - The company reported a revenue of $257 million for the year ending December 31, 2025, representing a year-on-year growth of 0.7% [2] - The profit attributable to shareholders was $6.793 million, showing a significant increase of 758.8% compared to the previous year [2] - Basic earnings per share were reported at $0.0034 [2] Revenue Breakdown - Revenue from North America and Europe experienced a slight decline, primarily due to a decrease in earnings from drug discovery services [2] - The decline in North American and European revenue was attributed to pharmaceutical and biotechnology companies optimizing their R&D portfolios and cautiously controlling development expenditures [2] - Strong demand for laboratory testing services partially offset the revenue decline in these regions [2] Growth in China - Revenue growth in China was driven by improved capacity utilization and the company's marketing efforts [2]

Core Viewpoint - Fangda Holdings (01521.HK) reported a slight increase in revenue for the fiscal year ending December 31, 2025, with earnings rising from approximately $255 million to about $257 million, reflecting a 0.7% growth. The net profit surged to around $6.8 million, a significant increase of 1033.3% compared to the previous year's net profit of approximately $600,000. Basic earnings per share stood at $0.0034 [1]. Revenue Performance - The group's revenue for the fiscal year ending December 31, 2025, increased to approximately $257 million from about $255 million for the fiscal year ending December 31, 2024, marking a 0.7% growth [1]. - The net profit for the fiscal year ending December 31, 2025, was approximately $6.8 million, a substantial rise of 1033.3% from the net profit of around $600,000 for the fiscal year ending December 31, 2024 [1]. Business Segment Analysis - Revenue from North America and Europe experienced a slight decline, primarily due to decreased earnings from the drug discovery business, which was negatively impacted by pharmaceutical and biotechnology companies optimizing their R&D portfolios and cautiously controlling development expenditures [1]. - However, strong demand for laboratory testing services partially offset the decline in revenue from the drug discovery segment [1].

智通财经APP讯，方达控股(01521)发布截至2025年12月31日止年度业绩，该集团取得收益2.57亿美元， 同比增长0.7%;公司拥有人应占溢利679.3万美元，同比增长758.8%;每股基本盈利0.0034美元。 公告称，北美及欧洲业务收益略有减少，主要由于药物发现业务产生的收益下降所致。此乃受到制药及 生物技术公司持续优化研发组合及谨慎控制开发支出的负面影响。然而，实验室检测服务相当强劲的需 求部分抵销了该跌幅。中国业务的收益增长主要由于产能利用率有所提升及集团在营销方面的努力。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 全年業績公告 截至2025年12月31日止年度 | 財務摘要 | | | | | | --- | --- | --- | --- | --- | | | | 2025年 | 2024年 | 變動 | | | | 百萬美元 | 百萬美元 | | | 收益 | | 256.7 | 254.9 | 0.7% | | 毛利 | | 69.2 | 69.8 | (0.9)% | | 毛利率 | | 27.0% | 27.4% | | | 稅息折舊及攤銷前利潤 | | 54.0 | 50.0 | 8.0% | | 稅息折舊及攤銷前利潤率 | | 21.1% | 19.6% | | | 經調整稅息折舊及攤銷前利潤 | | 55.8 | 54.0 | 3.3% | | 經調整稅息折舊及攤 ...

格隆汇3月17日丨方达控股(01521.HK)公告，谨定于2026年3月30日(星期一)举行董事会会议，以(其中包 括)考虑及通过公司及其附属公司截至2025年12月31日止的年度全年业绩，及考虑建议派发末期股息(如 有)。 ...

格隆汇3月17日丨方达控股(01521.HK)发布公告，谨定于2026年3月30日（星期一）举行董事会会议，以 （其中包括）考虑及通过公司及其附属公司截至2025年12月31日止的年度全年业绩，及考虑建议派发末 期股息（如有）。 ...

方達控股公司* （於開曼群島註冊成立的有限公司） （股份代號：1521） 董事會召開日期 方達控股公司*（「本公司」）董事會（「董事會」）茲通告謹定於2026年3月30日（星期 一）舉行董事會會議，以（其中包括）考慮及通過本公司及其附屬公司截至2025年 12月31日止的年度全年業績，及考慮建議派發末期股息（如有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 FRONTAGE HOLDINGS CORPORATION 香港，2026年3月17日 截至本公告日期，董事會成員包括執行董事李松博士、Wentao Zhang博士及 Zhongping Lin博士；非執行董事Yin Zhuan女士及吳灝先生；及獨立非執行董事 李軼梵先生、劉二飛先生及王勁松博士。 * 僅供識別 承董事會命 方達控股公司* 主席 李松博士 ...

Group 1 - On March 3, 2026, Fonda Holdings, a subsidiary of Tiger Med Group, announced the completion of its acquisition of Guanhua Medical, enhancing Fonda's global central laboratory capabilities and service capacity in China and the Asia-Pacific region [1] - Guanhua Medical is a leading clinical research laboratory service provider in China, having supported over 1,500 clinical trials across multiple therapeutic areas, and has extensive experience in regulatory compliance and high-quality laboratory testing services [1] - Following the acquisition, Fonda Holdings aims to expand its central laboratory network in China and improve its comprehensive support for domestic clinical research and multi-regional clinical trials (MRCT) [1] Group 2 - A representative from Fonda Holdings stated that the integration of Guanhua Medical is a significant step in Fonda's global development, aligning with Fonda's commitment to quality and compliance standards [2] - The acquisition is part of Fonda Holdings' ongoing efforts to enhance its global footprint, leveraging a unified quality system and operational standards to improve collaboration between China and the U.S. and accelerate the delivery of innovative drugs to international markets [2] Group 3 - Fonda Holdings is a comprehensive pharmaceutical R&D CRO with established centers in China, North America, and Europe, providing a wide range of services including drug chemistry, pharmacology, DMPK, and clinical research [3] - The company adheres to a "global unified quality system" and has successfully passed over 350 audits from regulatory agencies, including more than 200 from the FDA, over its 25 years of operation [3]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 方達控股公司 (於開曼群島註冊成立的有限公司) 足夠公眾持股量的確認(註4) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01521 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.000 ...

方达控股(01521)发布公告，就有关本公司全资附属公司方达上海拟2.7亿元收购上海观合医药科技股份 有限公司(目标公司)的相关事宜。股份转让协议所载的所有先决条件均已达成，且根据股份转让协议的 条款及条件，交割已于2026年3月3日作实。交割后，目标公司已成为本公司全资附属公司，而目标公司 及其附属公司的财务业绩将综合入账至本集团财务报表。 ...